FTISADTSK (acetate)

FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) [1].

C44H72N10O18

1029.1

O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](N)CC1=CC=CC=C1)=O)=O.CC(O)=O

Drug Metabolite

99.66

H2O : 50 mg/mL (ultrasonic)

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Blue Ice